Olema Oncology has announced exciting new preclinical combination data that will be showcased at the forthcoming 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. This annual symposium is renowned for highlighting transformative research findings in the field of oncology.
The company will present compelling data indicating the efficacy of palazestrant, a selective estrogen receptor downregulator, when combined with two targeted agents: capivasertib, an AKT inhibitor, and everolimus, an mTOR inhibitor. These findings provide insight into the potential of palazestrant to enhance antitumor activity and overcome resistance mechanisms in specific cancer types.
Additionally, Olema will present data on OP-3136, their novel KAT6 inhibitor, demonstrating its potential synergistic effects when combined with palazestrant and other targeted therapies. The combination studies aim to explore OP-3136’s role in augmenting the therapeutic impact of these agents, paving the way for innovative treatment strategies.
“Our preclinical data highlight the promising potential of these combinations to improve outcomes for patients facing treatment challenges,” said Dr. Insert Name, Insert Position at Olema Oncology. At this year’s symposium, we look forward to sharing our findings with the global oncology community and discussing how these combinations can ultimately inform future clinical studies.
The EORTC-NCI-AACR Symposium serves as a platform for researchers and industry leaders to present cutting-edge cancer research findings. Olema’s presentation is expected to garner significant interest, given the urgency for new therapeutic strategies in oncology.
As the need for innovative cancer therapies continues to grow, Olema Oncology is committed to advancing its research programs and exploring novel combination approaches that can improve patient care and treatment efficacy. The preclinical data presented at the symposium will contribute valuable insights to the ongoing discussions and research efforts surrounding cancer therapeutics.
Olema Oncology’s commitment to pioneering research reinforces its position as a vital player in the oncology landscape, striving to deliver new hope for patients and revolutionizing treatment paradigms.
Stay tuned for more updates from the symposium as Olema Oncology, along with other industry leaders, continues to advance the field of cancer research.
Comments